Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

The tools and techniques may have changed, but financial fraud is as pervasive as ever.

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Merck (NYSE:MRK) is discontinuing two late-stage trials evaluating Keytruda-based therapies for cancer treatment, as benefit/risk profile did not support continuing the trials. Based on the ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...

(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I’m in New York this week with my colleague Adam ...

But it’s an issue that scientists discussing the trials raised throughout ESMO. Merck partnered with Eisai back in 2018 to expand the latter company’s Lenvima into new cancer indications ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Recommended Reading Biomarker data help Merck case for wide use of Keytruda combo Merck & Co.’s drug ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...